27392483|t|Liver - specific mono-unsaturated fatty acid synthase-1 inhibitor for anti-hepatitis C treatment
27392483|a|Recently, direct antiviral agents against hepatitis C virus (HCV) infection have been developed as highly effective anti-HCV drugs. However, the appearance of resistant viruses against direct anti-viral agents is an unsolved problem. One of the strategies considered to suppress the emergence of the drug-resistant viruses is to use drugs inhibiting the host factor, which contributes to HCV proliferation, in combination with direct anti-viral agents. The replication complex was reported to be present in the membranous compartment in the cells. Thus, lipid metabolism modulators are good candidates to regulate virus assembly and HCV replication. Recent studies have shown that stearoyl-CoA desaturase (SCD), an enzyme for long-chain mono-unsaturated fatty acid (LCMUFA) synthesis, is a key factor that defines HCV replication efficiency. Systemic exposure to SCD-1 inhibor induces some side effects in the eyes and skin. Thus, systemic SCD-1 inhibitors are considered inappropriate for HCV therapy. To avoid the side effects of systemic SCD-1 inhibitors, the liver - specific SCD-1 inhibitor, MK8245, was synthesized; it showed antidiabetic effects in diabetic model mice with no side effects. In the phase 1 clinical study on measurement of MK8245 tolerability, no significant side effects were reported (ClinicalTrials.gov Identifier: NCT00790556). Therefore, we thought liver - specific SCD-1 inhibitors would be suitable agents for HCV - infected patients. MK8245 was evaluated using recombinant HCV culture systems. Considering current HCV treatments, to avoid the emergence of direct anti-viral agents - resistant viruses, combination therapy with direct anti-viral agents and host - targeted agents would be optimal. With this viewpoint, we confirmed MK8245 's additive or synergistic anti-HCV effects on current direct anti-viral agents and interferon-alpha therapy. The results suggest that MK8245 is an option for anti-HCV multi-drug therapy with a low risk of emergence of drug-resistant HCV without significant side effects.
27392483	0	5	Liver	T023	C0023884
27392483	8	16	specific	T080	C0205369
27392483	17	55	mono-unsaturated fatty acid synthase-1	T116,T126	C0015683
27392483	56	65	inhibitor	T121	C0014432
27392483	70	86	anti-hepatitis C	T033	C0243095
27392483	87	96	treatment	T061	C0087111
27392483	114	130	antiviral agents	T121	C0003451
27392483	131	138	against	T080	C0521124
27392483	139	172	hepatitis C virus (HCV) infection	T047	C4288963
27392483	196	202	highly	T080	C0205250
27392483	203	212	effective	T080	C1704419
27392483	213	227	anti-HCV drugs	T121	C4020634
27392483	242	252	appearance	T080	C0700364
27392483	256	265	resistant	T169	C0332325
27392483	266	273	viruses	T005	C0042776
27392483	274	281	against	T080	C0521124
27392483	289	306	anti-viral agents	T121	C0003451
27392483	313	321	unsolved	T077	C1710576
27392483	322	329	problem	T033	C0033213
27392483	353	363	considered	T078	C0750591
27392483	367	375	suppress	T169	C1260953
27392483	380	389	emergence	T080	C0700364
27392483	397	411	drug-resistant	T038	C0013203
27392483	412	419	viruses	T005	C0042776
27392483	430	435	drugs	T121	C1254351
27392483	436	446	inhibiting	T052	C3463820
27392483	451	455	host	T001	C1167395
27392483	456	462	factor	T169	C1521761
27392483	485	488	HCV	T005	C0220847
27392483	489	502	proliferation	T169	C1514485
27392483	531	548	anti-viral agents	T121	C0003451
27392483	554	573	replication complex	T026	C1167179
27392483	593	600	present	T033	C0150312
27392483	608	618	membranous	T080	C0205287
27392483	619	630	compartment	T082	C1948049
27392483	638	643	cells	T025	C0007634
27392483	651	667	lipid metabolism	T044	C0598783
27392483	668	678	modulators	T121	C1254351
27392483	702	710	regulate	T169	C2587213
27392483	711	725	virus assembly	T038	C0282629
27392483	730	733	HCV	T005	C0220847
27392483	734	745	replication	T043	C0042774
27392483	778	801	stearoyl-CoA desaturase	T116,T126	C0038233
27392483	803	806	SCD	T116,T126	C0038233
27392483	812	818	enzyme	T116,T126	C0014442
27392483	823	861	long-chain mono-unsaturated fatty acid	T109,T123	C0015687
27392483	863	869	LCMUFA	T109,T123	C0015687
27392483	871	880	synthesis	T038	C0220781
27392483	891	897	factor	T169	C1521761
27392483	911	914	HCV	T005	C0220847
27392483	915	926	replication	T043	C0042774
27392483	927	937	efficiency	T081	C0013682
27392483	939	947	Systemic	T169	C0205373
27392483	948	959	exposure to	T080	C0332157
27392483	960	965	SCD-1	T116,T126	C0038233
27392483	966	973	inhibor	T121	C0014432
27392483	974	981	induces	T169	C0205263
27392483	987	999	side effects	T046	C0041755
27392483	1007	1011	eyes	T023	C0015392
27392483	1016	1020	skin	T022	C1123023
27392483	1028	1036	systemic	T169	C0205373
27392483	1037	1042	SCD-1	T116,T126	C0038233
27392483	1043	1053	inhibitors	T121	C0014432
27392483	1058	1068	considered	T078	C0750591
27392483	1069	1082	inappropriate	T080	C1548788
27392483	1087	1090	HCV	T047	C4288963
27392483	1091	1098	therapy	T169	C0039798
27392483	1113	1125	side effects	T046	C0041755
27392483	1129	1137	systemic	T169	C0205373
27392483	1138	1143	SCD-1	T116,T126	C0038233
27392483	1144	1154	inhibitors	T121	C0014432
27392483	1160	1165	liver	T023	C0023884
27392483	1168	1176	specific	T080	C0205369
27392483	1177	1182	SCD-1	T116,T126	C0038233
27392483	1183	1192	inhibitor	T121	C0014432
27392483	1194	1200	MK8245	T109,T121	C3252063
27392483	1206	1217	synthesized	T052	C1883254
27392483	1229	1249	antidiabetic effects	T033	C0243095
27392483	1253	1261	diabetic	T033	C0241863
27392483	1262	1272	model mice	T015	C0025929
27392483	1278	1280	no	T033	C1513916
27392483	1281	1293	side effects	T046	C0041755
27392483	1302	1309	phase 1	T079	C0439559
27392483	1310	1324	clinical study	T062	C0008972
27392483	1328	1339	measurement	T169	C0242485
27392483	1343	1349	MK8245	T109,T121	C3252063
27392483	1350	1362	tolerability	T062	C3274448
27392483	1364	1378	no significant	T033	C1273937
27392483	1379	1391	side effects	T046	C0041755
27392483	1407	1425	ClinicalTrials.gov	T170	C4086204
27392483	1474	1479	liver	T023	C0023884
27392483	1482	1490	specific	T080	C0205369
27392483	1491	1496	SCD-1	T116,T126	C0038233
27392483	1497	1507	inhibitors	T121	C0014432
27392483	1517	1525	suitable	T080	C3900053
27392483	1526	1532	agents	T121	C1254351
27392483	1537	1540	HCV	T005	C0220847
27392483	1543	1551	infected	T033	C0439663
27392483	1552	1560	patients	T101	C0030705
27392483	1562	1568	MK8245	T109,T121	C3252063
27392483	1589	1604	recombinant HCV	T005	C0597363
27392483	1605	1620	culture systems	T063	C1516329
27392483	1634	1641	current	T079	C0521116
27392483	1642	1645	HCV	T005	C0220847
27392483	1646	1656	treatments	T061	C0087111
27392483	1671	1680	emergence	T080	C0700364
27392483	1691	1708	anti-viral agents	T121	C0003451
27392483	1711	1720	resistant	T169	C0332325
27392483	1721	1728	viruses	T005	C0042776
27392483	1730	1749	combination therapy	T061	C0009429
27392483	1762	1779	anti-viral agents	T121	C0003451
27392483	1784	1788	host	T001	C1167395
27392483	1791	1799	targeted	T169	C1521840
27392483	1800	1806	agents	T121	C1254351
27392483	1816	1823	optimal	T080	C2698651
27392483	1849	1858	confirmed	T080	C0521093
27392483	1859	1865	MK8245	T109,T121	C3252063
27392483	1869	1877	additive	T080	C0442796
27392483	1881	1892	synergistic	T080	C2986495
27392483	1893	1909	anti-HCV effects	T033	C0243095
27392483	1928	1945	anti-viral agents	T121	C0003451
27392483	1950	1974	interferon-alpha therapy	T061	C0854621
27392483	1980	1987	results	T169	C1274040
27392483	2001	2007	MK8245	T109,T121	C3252063
27392483	2014	2020	option	T169	C1518601
27392483	2025	2033	anti-HCV	T033	C0243095
27392483	2034	2052	multi-drug therapy	T061	C0013216
27392483	2064	2068	risk	T078	C0035647
27392483	2072	2081	emergence	T080	C0700364
27392483	2085	2099	drug-resistant	T038	C0013203
27392483	2100	2103	HCV	T005	C0220847
27392483	2112	2123	significant	T078	C0750502
27392483	2124	2136	side effects	T046	C0041755